Crizotinib in ROS1-rearranged non-small-cell lung cancer
Carcinoma, Non-Small-Cell Lung
Protein Kinase Inhibitors
In this study, crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC. ROS1 rearrangement defines a second molecular subgroup of NSCLC for which crizotinib is highly active. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).